Adocia strengthens its cash position by 19 million euros following a real estate transaction
28 mars 2022 12h00 HE
|
Adocia SA
The Company announces the sale of its building in Lyon in a sale and leaseback transaction worth over 20 million eurosThis transaction results in a net cash inflow of 19 million euros and is...
Adocia announces 2021 fourth quarter financial results
23 févr. 2022 12h00 HE
|
Adocia SA
LYON, France, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company specialized in the development of innovative formulations of...
Adocia announces its financial calendar for 2022
06 janv. 2022 12h00 HE
|
Adocia SA
LYON, France, Jan. 06, 2022 (GLOBE NEWSWIRE) -- ADOCIA SA, a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) a clinical stage...
Adocia’s partner Tonghua Dongbao Receives Clearance to Start Ultra-Rapid Insulin BioChaperone® Lispro Phase 3 Trial to Treat Type 1 and Type 2 Diabetes in China
14 oct. 2021 01h30 HE
|
Adocia SA
This Phase 3 clinical program will enroll over 1,300 people with diabetes and is expected to be pivotal for product registration in ChinaFirst patient in the study will trigger a milestone payment to...
Adocia在1型糖尿病患者中启动BC LisPram通过泵给药的1期临床试验
29 juin 2021 12h00 HE
|
Adocia SA
首次在单个泵中测试与血糖控制相关的两个关键激素，即速效胰岛素类似物和淀粉类似物的独特组合，BioChaperone® 赖脯胰岛素和普兰林肽联合制剂的安全性、药代动力学和血糖控制能力将与赖脯胰岛素进行比较 里昂, June 30, 2021 (GLOBE NEWSWIRE) -- Adocia (巴黎泛欧交易所: FR0011184241 – ADOC),...
Adocia Initiates BC LisPram Phase 1 Clinical Trial in Pump for People with Type 1 Diabetes
29 juin 2021 12h00 HE
|
Adocia SA
For the first time, a unique combination of two key hormones involved in glycemic control, a rapid acting insulin analog and an amylin analog, is tested in a single pumpBioChaperone® Lispro and...
泵给药短效多激素组合专利申请将Adocia临床研究扩展到肥胖症领域
26 mai 2021 01h30 HE
|
Adocia SA
已申请三项专利系列涵盖新型激素组合：普兰林肽-艾塞那肽和胰高血糖素-艾塞那肽——两种组合在肥胖症治疗中均显示出令人鼓舞的效果通过泵输注短效激素可以增强患者授权，使患者可以优化治疗的获益/风险比这些配方也可以用于治疗其他代谢性疾病，例如NASH（非酒精性脂肪性肝炎），2型糖尿病或神经退行性疾病 里昂, May 26, 2021 (GLOBE NEWSWIRE) -- Adocia...
Adocia Expands Clinical Development to Obesity with Patent Applications on Short-Acting Multihormonal Combinations Administered by Pumps
26 mai 2021 01h30 HE
|
Adocia SA
Three patent families have been filed to cover novel hormonal combinations: pramlintide-exenatide and glucagon-exenatide – both combinations demonstrated promising effects in obesity...